Skip to content

Mifepristone and misoprostol versus misoprostol alone for uterine evacuation after early pregnancy failure: a pilot study

Mifepristone and misoprostol versus misoprostol alone for uterine evacuation after early pregnancy failure: a pilot study - M&M trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON43323
Enrollment
40
Registered
2016-05-31
Start date
2016-10-03
Completion date
Unknown
Last updated
2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

early pregnancy failure miscarriage

Interventions

After randomization at day 1 : - Mifepristone 600mg in the intervention group - placebo in the control group followed by the standard treatment with misoprostol : two doses of 400ug orally at da

Sponsors

Radboud Universitair Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: * Early pregnancy failure, 6-14 weeks postmenstrual with a o Crown-rump length * 6mm and no cardiac activity OR o Gestational sac without embryonic pole, confirmed by a second ultrasound at least one week later * At least one week after diagnosis OR a discrepancy of at least one week between crown-rump length and calendar gestational age * Intra-uterine pregnancy * Women aged above 18 years * Hemodynamic stable patient * No signs of infection * No signs of incomplete abortion * No contraindications for mifepristone or misoprostol * No high risk of thrombosis

Exclusion criteria

Exclusion criteria: Patient does not meet inclusion criteria, discovered after randomization Inability to give informed consent

Design outcomes

Primary

MeasureTime frame
The primary outcome will be complete evacuation of the products of conception from the uterus, which is determined by routinely ultrasonography six to nine days after treatment.

Secondary

MeasureTime frame
The secondary objectives are patient satisfaction, side effects and complications.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)